0973-7510 Journal of Pure and Applied Microbiology 2581-690X DR. M.N. Khan 10.22207/JPAM.15.1.11 A Multivalent Vaccine Containing Actinobacillus pleuropneumoniae and Mycoplasma hyopneumoniae Antigens Elicits Strong Immune Responses and Promising Protection in Pigs Dao Hoai Thu Shin Woo-Sung Do Van Tan Truong Quang Lam Choi Jong-Young Hahn Tae-Wook College of Veterinary Medicine and Institute of Veterinary Science, Kangwon National University, Chuncheon 24341, Korea. Innovac Co., Kangwon National University, 1 Kangwondaehak-gil, Chuncheon 24341, Korea. Key Laboratory of Veterinary Biotechnology, Faculty of Veterinary Medicine, Vietnam National University of Agriculture, Hanoi, Vietnam. Dodam Veterinary Clinics, Seoul 04716, Korea. Institute of Veterinary Research and Development of Central Vietnam, Vietnam. 02 02 2021 15 1 164 174 Copyright © 2021 The Author(s) 2021 This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.https://creativecommons.org/licenses/by/4.0/

Actinobacillus pleuropneumoniae (App) and Mycoplasma hyopneumoniae (Mhp) cause porcine pleuropneumonia and mycoplasmal pneumonia, respectively, and have serious impacts on the swine industry because they retard the growth of pigs. To protect pigs against these diseases, we have developed a multivalent vaccine consisting of App bacterins, APP RTX toxins (Apx toxins), and Mhp bacterin and adhesin protein. This vaccine induced the production of higher levels of antibodies against App and Mhp than the commercial vaccine (Nisseiken Swine APM Inactivated Vaccine). Furthermore, the vaccine efficiently protected pigs against virulent App challenge, showing promise as an efficient vaccine for the prevention of two important respiratory diseases, porcine pleuropneumonia and mycoplasmal pneumonia.

Keywords Actinobacillus pleuropneumoniae Mycoplasma hyopneumoniae multivalent vaccine immune responses protection efficacy